Niaid preclinical development support- cgmp manufacturing of PGT121 and PGDM1400 antibodies
Active Awarded Last action
- Contract number
- 75N93018F00009
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $12,942,880
Award facts
- Opportunity
-
- NIHAI2015035 Solicitation number
- Contract value 100% obligated
- $12,942,880.00 Current and potential, with all options
- Completion date 61% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $495,019 | |
| Funding Only Action | $180,640 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $182,226 | |
| Funding Only Action | $0 | |
| Change Order | $741,241 | |
| Funding Only Action | $470,027 | |
| Change Order | $1,854,650 | |
| Terminate for Convenience | -$310,818 | |
| Exercise an Option | $5,155,395 | |
| Original award | $4,174,500 |
Show all 12
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order contract to Advanced Bioscience Laboratories, Inc. (ABL) on August 9, 2018, with a ceiling value of $12.9 million for current Good Manufacturing Practice (cGMP) manufacturing of PGT121 and PGDM1400 antibodies in support of preclinical development activities. The contract, which carries a cost-plus-fixed-fee pricing structure with no set-aside designation, is scheduled for completion by December 31, 2031, and will be performed in Rockville, Maryland. These monoclonal antibodies are broadly neutralizing antibodies of significant interest to HIV prevention and treatment research, aligning with NIAID's mission to develop medical countermeasures for infectious diseases.
ABL is a contract research and manufacturing organization specializing in biopharmaceutical development with extensive experience in cGMP manufacturing, process development, analytical testing, and quality assurance services. The company has established itself as a key provider to multiple NIH institutes through several indefinite delivery vehicles, including substantial contracts with NIAID for diagnostic pre-clinical services ($24 million) and pediatric HIV prevention science support ($98.9 million). This delivery order falls under ABL's broader portfolio of work supporting NIAID's preclinical and clinical development programs for infectious disease countermeasures, leveraging the company's proven capabilities in manufacturing complex biologics for government-sponsored research initiatives.
Quick answers
Who was awarded contract 75N93018F00009?
75N93018F00009 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 9, 2018.
How much is contract 75N93018F00009 worth?
The government has obligated $12,942,880 on 75N93018F00009.
Is contract 75N93018F00009 an order under another contract?
Yes. 75N93018F00009 is a delivery order under HHSN272201700010I, an indefinite delivery contract.
Was contract 75N93018F00009 competed?
The extent of competition for 75N93018F00009 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award